CC-90003 is primarily investigated for its potential in cancer therapy, particularly acute myeloid leukemia (AML). It functions as a selective, irreversible inhibitor of the enzyme LSD1 (Lysine Specific Demethylase 1), which plays a crucial role in regulating gene expression associated with cancer cell growth and survival. By inhibiting LSD1, CC-90003 promotes cancer cell death and inhibits tumor progression and disease spread. This compound is being studied in clinical trials for its efficacy in treating various cancers, especially those with limited treatment options. Researchers are also exploring its use in combination therapies with other drugs to improve treatment outcomes and evaluate safety. The development of CC-90003 represents a promising avenue in precision medicine for oncology.